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explain the low proportion of endocarditis cases compared 
with vascular infections in the Dutch series (15% vs. 36%, as 
reported by Kampschreur et al. (1)) compared with the series 
in our center (68% vs. 20%; unpub. data).
Endocarditis and vascular infections, whose first symp-
toms may be fatal decompensation or stroke, can be prevented 
in Q fever patients by implementing systematic screening 
echocardiography, phase I IgG monitoring, and PET scanning 
of patients with vascular disease (10). In our experience, only 
1 patient with uncontrolled Q fever endocarditis has died since 
2006, when we began following this protocol (3). The patient 
had a cardiac valve replacement 1 year before dying, but his 
phase I IgG titer was low (1:200), and C. burnetii PCR for his 
valve was negative, so no treatment was prescribed.
Reanalysis of the Q fever literature by different teams 
has brought challenging concepts to light (7). In a series from 
the Netherlands (1), 4 patients were shown to have died from 
endocarditis and 2 from vascular infections. These patients 
may have had better outcomes if the methods we propose 
here had been followed. Conversely, high serologic titers are 
not definite proof of persistent focalized infection, as illus-
trated in an outbreak in French Guiana, where exceptionally 
high serologic titers have been observed, but persistent focal-
ized infections have rarely been diagnosed (10).
Accurate identification of persistent focalized C. bur-
netii infections will improve patient outcomes by preventing 
long-term, organ-specific, lethal complications (e.g., vascu-
lar infections are a risk for vascular rupture, lymphadenitis 
is a risk for lymphoma) and by avoiding drug side effects in 
patients with isolated elevated serologic test results. Clini-
cians should look beyond a diagnosis of chronic Q fever to 
determine whether a patient might have persistent focalized 
infection(s). The term fever in Q fever has evolved from a 
pathologic picture per se to a clinical epiphenomenon; it is 
now time to evolve from the concept of chronic Q fever to 
one of persistent focalized C. burnetii infection(s) (10).
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Among 42 gram-negative bloodstream isolates from inpa-
tients in 3 hospitals in Yangon, Myanmar, admitted during 
July–December 2014, 16 (38%) were extended-spectrum 
β-lactamase–producing Enterobacteriaceae and 6 (14%) 
produced carbapenemase. The high prevalence of multi-
drug-resistant gram-negative bacteria raises concerns about 
the empiric treatment of patients with sepsis in Yangon.
Infections with extended-spectrum β-lactamase (ESBL)–producing gram-negative bacteria and carbapenem-resis-
tant Enterobacteriaceae (CRE) have been reported worldwide 
(1). Little is known about the occurrence of ESBL-producing 
and CRE bacteria in Yangon, Myanmar. Therefore, we char-
acterized 42 gram-negative organisms isolated from routine 
blood cultures from adult inpatients in Yangon.
All bacteria had been isolated at the microbiology 
laboratories of 3 hospitals in Yangon during July–Decem-
ber 2014. During the study period, 592 blood cultures were 
processed, 536 from Yangon General Hospital (YGH) and 
56 from 2 private hospitals. YGH is a 2,000-bed tertiary re-
ferral and teaching hospital in Yangon, providing free hos-
pital care to civilians. The 2 private hospitals have 350 and 
100 beds and provide secondary-level medical and surgical 
services to paying patients. 
Of the 592 blood cultures, 42 (7.8%) yielded gram-
negative bacteria, 28 (67%) from YGH and 14 (33%) 
from the 2 private hospitals. No clinical information was 
available about the patients from whom the cultures were 
taken. The identity and antimicrobial drug susceptibility 
of isolates were confirmed at Southern Community Labo-
ratories (Dunedin, New Zealand) by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry 
(Microflex LT; Bruker Daltonics, Billerica, MA, USA), 
disc diffusion testing using the Clinical and Laboratory 
Standards Institute  method (2), and the Phoenix Auto-
mated Microbiology System (Bruker Daltonics) (panel 
NMIC/ID-95).
We conducted phenotypic confirmation of ESBL pro-
duction on cefpodoxime-resistant isolates using cefotaxi-
me and ceftazidime with and without clavulanic acid and 
that of carbapenmase production on meropenem-resistant 
isolates by modified Hodge test according to Clinical and 
Laboratory Standards Institute criteria (2). We performed 
PCR for β-lactamase genes on all ESBL- and potential 
carbapenemase-producing organisms (3,4). We conducted 
bidirectional Sanger sequencing of amplicons and identi-
fied DNA sequences by BLAST (https://blast.ncbi.nlm.nih.
gov/Blast.cgi) and by comparison with known β-lactamase 
gene sequences.
Of the 42 isolates, 34 (81%) were Enterobacteriaceae 
(20 Escherichia coli, 7 Klebsiella pneumoniae, 6 Salmonella 
enterica, and 1 Enterobacter cloacae) and 8 (19.0%) were 
nonfermenting gram-negative bacilli. Of the Enterobacteria-
ceae, 20 (59%) were multidrug resistant (MDR), with resis-
tance to >3 classes of antimicrobial drugs, and 7 (21%) were 
extensively drug resistant, with susceptibility to <2 classes 
of antimicrobial drugs (5). All MDR Enterobacteriaceae 
were susceptible to polymyxin (Table). Phenotypic testing 
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Table. Antimicrobial drug susceptibility of Enterobacteriaceae and Acinetobacter spp. isolated from blood cultures of inpatients from 3 
hospitals in Yangon, Myanmar, 2014* 
Agent 
Organism, no. (%) susceptible 
Escherichia coli, 
n = 20 
Klebsiella 
pneumoniae, n = 7 
Salmonella 
enterica, n = 6 
Enterobacter cloacae, 
n = 1 
Acinetobacter spp., 
n = 3 
Ampicillin 2 (10) 0 6 (100) 0 NT 
Amoxicillin/clavulanic acid 5 (25) 1 (14) 6 (100) 0 NT 
Piperacillin/tazobactam 13 (65) 2 (29) 6 (100) 0 2 (67) 
Cefuroxime 5 (25) 1 (14) NT 0 NT 
Ceftriaxone 6 (30) 1 (14) 6 (100) 0 1 (33) 
Ceftazidime 6 (30) 1 (14) 6 (100) 0 0 
Cefipime 7 (35) 1 (14) 6 (100) 0 2 (67) 
Cefoxitin 11 (55) 4 (57) NT 0 NT 
Aztreonam 6 (30) 1 (14) 6 (100) 0 NT 
Ertapenem 17 (85) 4 (57) 6 (100) 1 (100) NT 
Imipenem 17 (85) 4 (57) 6 (100) 1 (100) 3 (100) 
Meropenem 17 (85) 4 (57) 6 (100) 1 (100) 3 (100) 
Gentamicin 14 (70) 2 (29) NT 1 (100) 2 (67) 
Tobramycin 9 (45) 1 (14) NT 0 3 (100) 
Ciprofloxacin 1 (5) 1 (14) 3 (43) 0 2 (67) 
Chloramphenicol 11 (55) 2 (29) 6 (100) 0 NT 
Colistin† 20 (100) 7 (100) 6 (100) 1 (100) 3 (100) 
Nitrofurantoin 16 (80) 1 (14) NT 0 NT 
Trimethoprim/ 
sulfamethoxazole 
2 (10) 2 (29) 6 (100) 0 2 (67) 
*NT, not tested. 
†Because there are no Clinical and Laboratory Standards Institute for susceptibility testing criteria for colistin for Enterobaceriaceae, European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) criteria were used (susceptible if MIC <2 mg/L, per EUCAST criteria version 6.0, 2016; 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf). 
 
suggested the presence of an ESBL in 16 (38%) and a car-
bapenemase in 6 (14%) of all gram-negative isolates. Mo-
lecular analysis showed that 13 (81%) ESBL-producing iso-
lates contained a group 1 CTX-M gene; all were confirmed 
as CTX-M-15 by sequencing. Carbapenemase-producing 
isolates, including 3 E. coli and 3 K. pneumoniae, contained 
the New Delhi metallo-β-lactamase (NDM) gene, sequenced 
as NDM-4 in 5 (83%) and NDM-7 in 1 (17%).
Our study revealed a high proportion of ESBL- and 
carbapenemase-producing organisms among gram-nega-
tive bloodstream isolates during the study period from hos-
pital inpatients in Yangon. Half of E. coli isolates and 43% 
of K. pneumoniae isolates produced ESBLs. This finding 
is consistent with the high proportion of ESBL production 
reported in isolates from India (>80%), China (>60%), 
and other Asia and Southeast Asia countries (>30%) (6). 
Carbapenemase production (15% in E. coli and 43% in K. 
pneumoniae) in this study was comparable to those previ-
ously reported from clinical isolates in India (7).
CTX-M-15 ESBL and NDM carbapenemase were the 
most prevalent mechanisms of resistance to β-lactams in 
our study. This finding is consistent with the current global 
dissemination of CTX-M-15 among E. coli isolates (8). All 
CRE isolates were NDM-4 or NDM-7. Two previous case 
reports have indicated the presence of NDM-producing En-
terobacteriaceae from travelers to Myanmar: 1 NDM-7 (9) 
and 1 NDM-4 (10).
Two thirds of all isolates included in this study origi-
nated from YGH, the largest public hospital in Myanmar. 
All CRE isolates and 14 (88%) of 16 ESBL producers were 
isolated from YGH; this may reflect a higher prevalence 
of colonization with MDR organisms among patients in 
YGH or they may be healthcare-associated infections. Of 
concern, at YGH 11 (73%) of 15 E. coli and 6 (100%) of 
6 K. pneumoniae isolates produced either an ESBL or car-
bapenemase; among these, 3 (20%) of 15 E. coli and 3 
(50%) of 6 K. pneumoniae isolates were NDM producers.
Whereas all 23 (100%) of the Enterobacteriaceae at 
YGH were susceptible to treatment with colistin, an empiric 
treatment regimen of meropenem plus gentamicin would 
have covered only 18 (78%) isolates. This finding highlights 
the difficulties with designing an effective empiric antimi-
crobial regimen for patients with suspected gram-negative 
sepsis in a setting of a high prevalence of antimicrobial re-
sistance, without providing further selective pressure for the 
spread of CRE and the emergence of colistin resistance.
Our study has limitations. First, clinical data were not 
prospectively collected, and it was not possible to obtain 
data retrospectively because of poor recording systems. 
Second, we cannot be certain that study isolates represent 
the population of organisms causing gram-negative sepsis 
in Yangon. However, the high proportion of ESBL- and 
carbapenemase-producing gram-negative bacteria among 
bloodstream isolates from hospitalized patients in Yangon 
raises concern for the treatment of patients with gram- 
negative sepsis and suggests a need to reduce selective 
pressure and control the spread of resistant organisms.
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